Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Cancer Survivors At Greater Risk Of Birth Complications; Special Monitoring Needed
Survivors of childhood cancer run particular risks when pregnant and should be closely monitored, the 25th annual conference of the European Society of Human Reproduction and Embryology heard today (Wednesday 1 July). Dr. Sharon Lie Fong, of the Department of Obstetrics and Gynaecology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands, said that, although such women may have conceived spontaneously and considered themselves to be perfectly healthy, their deliveries should always take place in a hospital.
generic viagra online
Jumping Genes Challenge Assumptions About Genetic Diseases Such As Cancer
Jumping genes do their jumping while the embryo is growing and not when sperm and eggs are developing, according to a new study by US
News of the day
Is It Time To Consider A Role For MRI Before Prostate Biopsy?
UroToday.com - The prevailing view is that MRI has a limited role in the management of prostate cancer. Currently, the threshold for requesting a pre-treatment staging MRI is variable with most advocating this for only those classified as high risk localized prostate cancer, although some also advocate men with intermediate risk disease.
Public Health

EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study

Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). For the dry eye clinical trial, EyeGate worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA. Over the past 30 years, Ora has been a pioneering force in the development of advanced research models across the field of ophthalmology. This Phase II single-center, randomized (105 patients), double-masked, placebo-controlled patient study evaluated the safety and efficacy of a corticosteroid solution (EGP-437) administered by the EyeGate® II Delivery System (at two dose levels) twice over a three-week period. Ora"s Controlled Adverse Environment (CAE) clinical research system, which simulates the acute environmental challenges regularly faced by DES patients, was used for this study. In the top-level analysis, investigators observed that EGP-437 significantly (p About Dry Eye Syndrome Dry Eye Syndrome (DES) is the most prevalent form of ocular discomfort and irritation, accounting for one in four patient visits to a general ophthalmologist. It is estimated that as many as 20 to 40 million Americans suffer from DES, including a significant number of patients who suffer from DES after Lasik surgery. Symptoms such as pain, light sensitivity, blurred vision, and irritation decrease the quality of life for patients and can ultimately lead to loss of function and blindness. The incidence of DES is increasing due to environmental factors, the aging population and the increasing prevalence of co-morbid diseases such as diabetes. There is no cure for DES, and the few treatment options currently available primarily provide temporary symptomatic relief. About Ora, Inc. Ora is the world"s leading independent ophthalmic drug and device development firm. Ora provides technology-based concept-to-market services and solutions that accelerate development timelines and improve the scientific quality of clinical research. Over the past 30 years, Ora has played a central role in the development and FDA approval of more than 30 ophthalmic products. For more information, please visit http://www.oraclinical.com. EyeGate Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009